Home › Companies › PLIANT THERAPEUTICS INC. › 2023-2024
Download data (CSV): ballot items · votes by manager · column guide.
Compiled from SEC Form N-PX filings and PLIANT THERAPEUTICS INC.’s Form 8-K, filed June 14, 2024 (Item 5.07 on EDGAR). Page generated November 20, 2026.
Meeting of June 13, 2024: 5 items on PLIANT THERAPEUTICS INC.’s Form 8-K, filed June 14, 2024: 1 approved · 3 passed (calculated) · 1 failed (calculated).
Significant dissent: 1 director (24.6% against); 1 say-on-pay vote (45.3% support).
Dissent tiers, on the company’s own Form 8-K tally (support = FOR ÷ (FOR + AGAINST), or FOR ÷ (FOR + WITHHELD) on a withhold ballot; abstentions and broker non-votes excluded): shareholder proposals with 15% support or more are notable, 25% significant, 40% high; director nominees with 10% or more against or withheld are notable, 20% significant; say-on-pay under 80% support is notable, under 70% significant; equity and compensation plans with 15% or more against are notable, 25% significant; any other item the board put forward with 15% or more against is notable. How this is decided
Proxy season: 2023-2024 2024-2025 2025-2026
Activist investors: Tang Capital (13D, 9.6%, as of March 10, 2025) · BML Capital (13F, 2.5%, as of September 30, 2026)
Explore PLIANT THERAPEUTICS INC. in the interactive database Compare manager voting policies
These tallies are PLIANT THERAPEUTICS INC.’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed June 14, 2024 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.
| Ballot item | For | Against | Abstain | Withheld | Broker non-votes | Support (of votes cast) | Reported outcome | Voting standard |
|---|---|---|---|---|---|---|---|---|
| Elect Director: Hoyoung Huh, M.D., Ph.D. | 39,087,800 | -- | -- | 12,731,485 | -- | 75% | Passed (calculated) | — |
| Elect Director: Darren Cline, MBA | 51,397,449 | -- | -- | 421,836 | -- | 99.2% | Passed (calculated) | — |
| Elect Director: David Pyott, MA, MBA | 48,388,729 | -- | -- | 3,430,556 | -- | 93% | Passed (calculated) | — |
| 2. Company's stockholders failed to approve, on a non-binding advisory basis, the compensation of the Company's named executive officers | 23,479,353 | 28,329,655 | 10,277 | -- | -- | 45.3% | Failed (calculated) | a majority of the votes cast |
| 3. The selection of Deloitte & Touche LLP as the Company's independent registered public accounting firm | 56,628,368 | 10,853 | 62,998 | -- | -- | 99.9% | Approved | — |
Source: PLIANT THERAPEUTICS INC., Form 8-K, filed with the SEC on June 14, 2024 — read the filing on EDGAR.
See voting trends for Health Care companies, 2023-2024: shareholder support by sector and by company size.
175 asset managers disclosed a vote on at least one PLIANT THERAPEUTICS INC. item in their SEC Form N-PX filings. Each item below shows how many of them voted on it, and how. Share totals are the shares those managers' funds voted, summed across every fund they report.
Combines 3 wordings of this item as funds reported it.
99.2% Majority: yes · of votes cast
Description as filed by funds: To elect three class III directors named in the proxy statement to our Board of Directors: Darren Cline, MBA
PLIANT THERAPEUTICS INC.’s own tally for this item (“Elect Director: Darren Cline, MBA”): 51,397,449 for, 421,836 withheld, per its Form 8-K filed June 14, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts: votes for exceeded votes against.
Support: 99.2% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.
The 58 asset managers below reported 12,940,290 for, 248,223 withheld.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 3,337,958 | 0 | 0 | 0 | For |
| T. Rowe Price | 2,805,430 | 0 | 0 | 0 | For |
| BlackRock | 1,479,278 | 0 | 0 | 0 | For |
| Capital Group | 1,377,327 | 0 | 0 | 0 | For |
| Fidelity | 903,542 | 0 | 0 | 0 | For |
| FRANKLIN STRATEGIC SERIES | 829,600 | 0 | 0 | 0 | For |
| Charles Schwab | 430,892 | 0 | 0 | 0 | For |
| Columbia Threadneedle | 310,308 | 0 | 0 | 0 | For |
| Dimensional | 0 | 0 | 0 | 183,701 | Withhold |
| Jackson National | 162,523 | 0 | 0 | 1,526 | For |
| Victory Capital | 160,127 | 0 | 0 | 0 | For |
| Equitable | 99,489 | 0 | 0 | 58,180 | Mixed |
| TIAA | 146,232 | 0 | 0 | 0 | For |
| State Street | 77,927 | 0 | 0 | 0 | For |
| Lincoln Financial | 74,516 | 0 | 0 | 2,509 | For |
| Russell Investments | 73,106 | 0 | 0 | 0 | For |
| American Century | 63,652 | 0 | 0 | 0 | For |
| WANGER ADVISORS TRUST | 58,436 | 0 | 0 | 0 | For |
| Nushares ETF Trust | 55,828 | 0 | 0 | 0 | For |
| ALGER FUNDS | 52,723 | 0 | 0 | 0 | For |
| John Hancock | 48,200 | 0 | 0 | 0 | For |
| QUANTITATIVE MASTER SERIES LLC | 44,225 | 0 | 0 | 0 | For |
| AIG/SunAmerica | 31,473 | 0 | 0 | 0 | For |
| Harbor Funds II | 30,605 | 0 | 0 | 0 | For |
| Global X | 25,868 | 0 | 0 | 0 | For |
Showing the 25 largest of 58 asset managers. All 58 are in the interactive database (link above).
Combines 3 wordings of this item as funds reported it.
93% Majority: yes · of votes cast
Description as filed by funds: To elect three class III directors named in the proxy statement to our Board of Directors: David Pyott, MA, MBA
PLIANT THERAPEUTICS INC.’s own tally for this item (“Elect Director: David Pyott, MA, MBA”): 48,388,729 for, 3,430,556 withheld, per its Form 8-K filed June 14, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts: votes for exceeded votes against.
Support: 93% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.
The 58 asset managers below reported 11,266,079 for, 1,922,434 withheld.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 3,337,958 | 0 | 0 | 0 | For |
| T. Rowe Price | 2,805,430 | 0 | 0 | 0 | For |
| BlackRock | 0 | 0 | 0 | 1,479,278 | Withhold |
| Capital Group | 1,377,327 | 0 | 0 | 0 | For |
| Fidelity | 881,098 | 0 | 0 | 22,444 | For |
| FRANKLIN STRATEGIC SERIES | 829,600 | 0 | 0 | 0 | For |
| Charles Schwab | 430,892 | 0 | 0 | 0 | For |
| Columbia Threadneedle | 310,308 | 0 | 0 | 0 | For |
| Dimensional | 0 | 0 | 0 | 183,701 | Withhold |
| Jackson National | 162,523 | 0 | 0 | 1,526 | For |
| Victory Capital | 160,127 | 0 | 0 | 0 | For |
| Equitable | 10,520 | 0 | 0 | 147,149 | Mixed |
| TIAA | 146,232 | 0 | 0 | 0 | For |
| State Street | 77,927 | 0 | 0 | 0 | For |
| Lincoln Financial | 74,516 | 0 | 0 | 2,509 | For |
| Russell Investments | 73,106 | 0 | 0 | 0 | For |
| American Century | 63,652 | 0 | 0 | 0 | For |
| WANGER ADVISORS TRUST | 58,436 | 0 | 0 | 0 | For |
| Nushares ETF Trust | 55,828 | 0 | 0 | 0 | For |
| ALGER FUNDS | 52,723 | 0 | 0 | 0 | For |
| John Hancock | 48,200 | 0 | 0 | 0 | For |
| QUANTITATIVE MASTER SERIES LLC | 0 | 0 | 0 | 44,225 | Withhold |
| AIG/SunAmerica | 31,473 | 0 | 0 | 0 | For |
| Harbor Funds II | 30,605 | 0 | 0 | 0 | For |
| Global X | 25,868 | 0 | 0 | 0 | For |
Showing the 25 largest of 58 asset managers. All 58 are in the interactive database (link above).
Combines 3 wordings of this item as funds reported it.
75% Majority: yes · of votes cast
Description as filed by funds: To elect three class III directors named in the proxy statement to our Board of Directors: Hoyoung Huh, M.D., Ph.D.
PLIANT THERAPEUTICS INC.’s own tally for this item (“Elect Director: Hoyoung Huh, M.D., Ph.D.”): 39,087,800 for, 12,731,485 withheld, per its Form 8-K filed June 14, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts: votes for exceeded votes against.
Support: 75% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.
The 58 asset managers below reported 12,257,179 for, 931,334 withheld.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 3,337,958 | 0 | 0 | 0 | For |
| T. Rowe Price | 2,805,430 | 0 | 0 | 0 | For |
| BlackRock | 1,479,278 | 0 | 0 | 0 | For |
| Capital Group | 1,377,327 | 0 | 0 | 0 | For |
| Fidelity | 903,542 | 0 | 0 | 0 | For |
| FRANKLIN STRATEGIC SERIES | 829,600 | 0 | 0 | 0 | For |
| Charles Schwab | 430,892 | 0 | 0 | 0 | For |
| Columbia Threadneedle | 310,308 | 0 | 0 | 0 | For |
| Dimensional | 0 | 0 | 0 | 183,701 | Withhold |
| Jackson National | 0 | 0 | 0 | 164,049 | Withhold |
| Victory Capital | 0 | 0 | 0 | 160,127 | Withhold |
| Equitable | 99,489 | 0 | 0 | 58,180 | Mixed |
| TIAA | 146,232 | 0 | 0 | 0 | For |
| State Street | 77,816 | 0 | 0 | 111 | For |
| Lincoln Financial | 47,300 | 0 | 0 | 29,725 | Mixed |
| Russell Investments | 73,106 | 0 | 0 | 0 | For |
| American Century | 0 | 0 | 0 | 63,652 | Withhold |
| WANGER ADVISORS TRUST | 58,436 | 0 | 0 | 0 | For |
| Nushares ETF Trust | 55,828 | 0 | 0 | 0 | For |
| ALGER FUNDS | 0 | 0 | 0 | 52,723 | Withhold |
| John Hancock | 27,082 | 0 | 0 | 21,118 | Mixed |
| QUANTITATIVE MASTER SERIES LLC | 44,225 | 0 | 0 | 0 | For |
| AIG/SunAmerica | 0 | 0 | 0 | 31,473 | Withhold |
| Harbor Funds II | 30,605 | 0 | 0 | 0 | For |
| Global X | 25,868 | 0 | 0 | 0 | For |
Showing the 25 largest of 58 asset managers. All 58 are in the interactive database (link above).
Combines 6 wordings of this item as funds reported it.
45.3% Majority: no · of votes cast
Prior year: 97.2% for (June 7, 2023 meeting) ▼ 51.9 pts
Description as filed by funds: TO APPROVE, BY NON-BINDING ADVISORY VOTE, THE RESOLUTION APPROVING NAMED EXECUTIVE OFFICER COMPENSATION.
PLIANT THERAPEUTICS INC.’s own tally for this item (“2. The Company's stockholders failed to approve, on a non-binding advisory basis, the compensation of the Company's named executive officers”): 23,479,353 for, 28,329,655 against, per its Form 8-K filed June 14, 2024 (Item 5.07). FOR was not more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Outcome: Failed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts using a majority of the votes cast, the standard stated in the company’s 8-K: votes for did not exceed votes against.
Support: 45.3% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
Voting standard, as the filing states it: a majority of the votes cast (“majority of the votes cast”).
Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 3,337,958 | 0 | 0 | 0 | For |
| T. Rowe Price | 0 | 2,805,430 | 0 | 0 | Against |
| BlackRock | 0 | 1,479,278 | 0 | 0 | Against |
| Capital Group | 0 | 1,377,327 | 0 | 0 | Against |
| Fidelity | 307,321 | 596,221 | 0 | 0 | Mixed |
| FRANKLIN STRATEGIC SERIES | 0 | 829,600 | 0 | 0 | Against |
| Charles Schwab | 0 | 430,892 | 0 | 0 | Against |
| Columbia Threadneedle | 0 | 310,308 | 0 | 0 | Against |
| Dimensional | 0 | 183,701 | 0 | 0 | Against |
| Jackson National | 0 | 164,049 | 0 | 0 | Against |
| Victory Capital | 0 | 160,127 | 0 | 0 | Against |
| Equitable | 0 | 157,669 | 0 | 0 | Against |
| TIAA | 0 | 146,232 | 0 | 0 | Against |
| State Street | 77,816 | 111 | 0 | 0 | For |
| Lincoln Financial | 47,300 | 29,725 | 0 | 0 | Mixed |
| Russell Investments | 0 | 73,106 | 0 | 0 | Against |
| American Century | 0 | 63,652 | 0 | 0 | Against |
| WANGER ADVISORS TRUST | 0 | 58,436 | 0 | 0 | Against |
| Nushares ETF Trust | 0 | 55,828 | 0 | 0 | Against |
| ALGER FUNDS | 0 | 52,723 | 0 | 0 | Against |
| John Hancock | 0 | 48,200 | 0 | 0 | Against |
| QUANTITATIVE MASTER SERIES LLC | 0 | 44,225 | 0 | 0 | Against |
| AIG/SunAmerica | 0 | 31,473 | 0 | 0 | Against |
| Harbor Funds II | 30,605 | 0 | 0 | 0 | For |
| Global X | 0 | 25,868 | 0 | 0 | Against |
Fund voting reports, all 58 managers: 3,805,035 for, 9,383,478 against. Showing the 25 largest; every one is in the interactive database (link above).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Deep Track Capital, LP | 4,415,343 | 0 | 0 | 0 | For |
| T. Rowe Price | 0 | 3,571,448 | 0 | 0 | Against |
| Redmile Group, LLC | 0 | 3,499,816 | 0 | 0 | Against |
| Laurion Capital Management LP | 0 | 3,474,744 | 0 | 0 | Against |
| First Light Asset Management, LLC | 3,276,945 | 0 | 0 | 0 | For |
| TRV GP IV, LLC | 2,132,867 | 0 | 0 | 0 | For |
| Fidelity | 2,077,288 | 0 | 0 | 0 | For |
| Polar Capital Holdings Plc | 0 | 1,989,220 | 0 | 0 | Against |
| GREAT POINT PARTNERS LLC | 1,725,936 | 0 | 0 | 0 | For |
| FRANKLIN ADVISERS INC | 0 | 1,513,287 | 0 | 0 | Against |
| Capital Group | 4 | 1,377,327 | 0 | 0 | Against |
| BlackRock | 20,114 | 1,229,197 | 0 | 0 | Against |
| PICTET ASSET MANAGEMENT SA | 0 | 1,189,593 | 0 | 0 | Against |
| State Street | 1,047,587 | 16,864 | 0 | 0 | For |
| BESSEMER TRUST Co NATIONAL ASSOCIATION | 0 | 1,059,388 | 0 | 0 | Against |
| RA CAPITAL MANAGEMENT, L.P. | 995,286 | 0 | 0 | 0 | For |
| Granahan Investment Management, LLC | 0 | 686,064 | 0 | 0 | Against |
| Citadel | 647,300 | 0 | 0 | 0 | For |
| GEODE CAPITAL MANAGEMENT, LLC | 0 | 646,434 | 0 | 0 | Against |
| Candriam S.C.A. | 0 | 548,000 | 0 | 0 | Against |
| Bessemer Trust CO of Delaware, N.A. | 0 | 541,619 | 0 | 0 | Against |
| BESSEMER TRUST CO | 0 | 532,079 | 0 | 0 | Against |
| BESSEMER TRUST Co OF FLORIDA | 0 | 532,079 | 0 | 0 | Against |
| Bessemer Trust Co of California, N.A. | 0 | 532,079 | 0 | 0 | Against |
| Bessemer Trust Co of Nevada, National Association | 0 | 532,079 | 0 | 0 | Against |
Institutional-manager reports, all 135 managers: 17,465,443 for, 26,004,033 against, 4,535 not voted. Showing the 25 largest; every one is in the interactive database (link above).
Combines 3 wordings of this item as funds reported it.
99.9% Approved · of votes cast
Prior year: 100.0% for (June 7, 2023 meeting) unchanged
Description as filed by funds: To ratify the appointment of Deloitte & Touche LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2023.
PLIANT THERAPEUTICS INC.’s own tally for this item (“3. The selection of Deloitte & Touche LLP as the Company's independent registered public accounting firm”): 56,628,368 for, 10,853 against — passed, per its Form 8-K filed June 14, 2024 (Item 5.07).
Reported outcome: Approved, in the filing’s own words: “Proposal 3: The Company's stockholders ratified the selection of Deloitte & Touche LLP as the Company's independent registered public accounting firm.”
Support: 99.9% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
The 58 asset managers below reported 13,188,513 for.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 3,337,958 | 0 | 0 | 0 | For |
| T. Rowe Price | 2,805,430 | 0 | 0 | 0 | For |
| BlackRock | 1,479,278 | 0 | 0 | 0 | For |
| Capital Group | 1,377,327 | 0 | 0 | 0 | For |
| Fidelity | 903,542 | 0 | 0 | 0 | For |
| FRANKLIN STRATEGIC SERIES | 829,600 | 0 | 0 | 0 | For |
| Charles Schwab | 430,892 | 0 | 0 | 0 | For |
| Columbia Threadneedle | 310,308 | 0 | 0 | 0 | For |
| Dimensional | 183,701 | 0 | 0 | 0 | For |
| Jackson National | 164,049 | 0 | 0 | 0 | For |
| Victory Capital | 160,127 | 0 | 0 | 0 | For |
| Equitable | 157,669 | 0 | 0 | 0 | For |
| TIAA | 146,232 | 0 | 0 | 0 | For |
| State Street | 77,927 | 0 | 0 | 0 | For |
| Lincoln Financial | 77,025 | 0 | 0 | 0 | For |
| Russell Investments | 73,106 | 0 | 0 | 0 | For |
| American Century | 63,652 | 0 | 0 | 0 | For |
| WANGER ADVISORS TRUST | 58,436 | 0 | 0 | 0 | For |
| Nushares ETF Trust | 55,828 | 0 | 0 | 0 | For |
| ALGER FUNDS | 52,723 | 0 | 0 | 0 | For |
| John Hancock | 48,200 | 0 | 0 | 0 | For |
| QUANTITATIVE MASTER SERIES LLC | 44,225 | 0 | 0 | 0 | For |
| AIG/SunAmerica | 31,473 | 0 | 0 | 0 | For |
| Harbor Funds II | 30,605 | 0 | 0 | 0 | For |
| Global X | 25,868 | 0 | 0 | 0 | For |
Showing the 25 largest of 58 asset managers. All 58 are in the interactive database (link above).
Ranked separately for each type of Form N-PX report. An institutional manager can report shares that a fund it advises also reports, so the two tables can list the same shares and are never added together. Each is ranked by the shares voted on the item that the most managers of that type reported, shown as a share of the 60,325,832 shares outstanding at the time of that meeting.
| # | Asset manager | % of shares outstanding |
|---|---|---|
| 1 | Vanguard | 5.53% |
| 2 | T. Rowe Price | 4.65% |
| 3 | BlackRock | 2.45% |
| 4 | Capital Group | 2.28% |
| 5 | Fidelity | 1.50% |
| 6 | FRANKLIN STRATEGIC SERIES | 1.38% |
| 7 | Charles Schwab | 0.71% |
| 8 | Columbia Threadneedle | 0.51% |
| 9 | Dimensional | 0.30% |
| 10 | Jackson National | 0.27% |
| # | Asset manager | % of shares outstanding |
|---|---|---|
| 1 | Deep Track Capital, LP | 7.32% |
| 2 | T. Rowe Price | 5.92% |
| 3 | Redmile Group, LLC | 5.80% |
| 4 | Laurion Capital Management LP | 5.76% |
| 5 | First Light Asset Management, LLC | 5.43% |
| 6 | TRV GP IV, LLC | 3.54% |
| 7 | Fidelity | 3.44% |
| 8 | Polar Capital Holdings Plc | 3.30% |
| 9 | GREAT POINT PARTNERS LLC | 2.86% |
| 10 | FRANKLIN ADVISERS INC | 2.51% |
As disclosed to the SEC in Form 13F (quarter-end holdings of 30 large managers), Schedules 13D and 13G (beneficial ownership above 5%) and the company’s own proxy statement (DEF 14A). Each row gives its source and the date its figure is as of: for Form 13F the quarter end it reports, for Schedules 13D and 13G the filing date, and for the proxy statement the date of its ownership table (or, where that date has not been read, the date the proxy was filed). The rows are therefore not all as of the same day.
| Holder | Shares | % outstanding | Source, as of |
|---|---|---|---|
| Deep Track Capital, LP | 5,750,000 | 9.53% | Proxy statement (DEF 14A), proxy filed April 22, 2024 |
| FMR LLC | 3,963,417 | 6.57% | Proxy statement (DEF 14A), proxy filed April 22, 2024 |
| T. Rowe Price | 3,959,088 | 6.56% | Form 13F, quarter ended March 31, 2024 |
| First Light Asset Management LLC | 3,634,510 | 6.02% | Proxy statement (DEF 14A), proxy filed April 22, 2024 |
| S F | 3,634,510 | 6.02% | Schedule 13G, filed February 14, 2024 |
| Laurion Capital Management LP | 3,583,567 | 5.94% | Proxy statement (DEF 14A), proxy filed April 22, 2024 |
| Morgan Stanley | 3,507,288 | 5.81% | Form 13F, quarter ended March 31, 2024 |
| Blue Owl Capital Holdings L.P. | 3,004,199 | 4.98% | Proxy statement (DEF 14A), proxy filed April 22, 2024 |
| Vanguard Group | 2,775,938 | 4.60% | Form 13F, quarter ended March 31, 2024 |
| JPMorgan Chase | 2,130,489 | 3.53% | Form 13F, quarter ended March 31, 2024 |
Percentages above are of 60,325,832 shares outstanding, as reported by PLIANT THERAPEUTICS INC. on its Form 10-Q dated May 1, 2024 (see the filing on EDGAR). This is the count contemporaneous with the 2023-2024 meeting, not today’s. Each holding is as of its own filing, which may be dated before or after the meeting.
At PLIANT THERAPEUTICS INC.'s shareholder meeting held June 13, 2024, in the 2023-2024 proxy season, 175 asset managers reported votes on at least one of its 5 ballot items in their SEC Form N-PX filings, covering 996 separate fund positions. On the most widely held item on that ballot — TO APPROVE, BY NON-BINDING ADVISORY VOTE, THE RESOLUTION APPROVING NAMED EXECUTIVE OFFICER… — FOR was 45.3% of the votes cast (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side), which is not more than half. Whether the item was approved is for the filing to say; that statement has not been read for this item. Source: PLIANT THERAPEUTICS INC.'s Form 8-K, Item 5.07, filed with the U.S. Securities and Exchange Commission on June 14, 2024.
Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered funds disclose how they voted every proxy and institutional managers disclose their votes on executive pay (say-on-pay, say-on-frequency and golden parachutes), and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from PLIANT THERAPEUTICS INC.’s 10-Q dated May 1, 2024. This page is a static snapshot rebuilt weekly on November 20, 2026; a live search always shows the current data.
PLIANT THERAPEUTICS INC. proxy season coverage: 2023-2024 (this page) · 2024-2025 · 2025-2026.
Proxy Votes Now, “PLIANT THERAPEUTICS (PLRX) 2024 Annual Meeting: Vote Results”, https://proxyvotesnow.com/company/pliant-therapeutics-inc/2024 (version of November 20, 2026). Derived from SEC Form N-PX and Form 8-K filings; tables licensed CC BY 4.0. Licence: CC BY 4.0.